Abstract Details

Title Mortality in Restless Leg Syndrome: A-11 year-year follow up study.

Topic Movement Disorders

Presentation(s) P16 - Poster Session 16 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-006

Objective To investigate survival in patients with Restless Leg Syndrome (RLS).

Background Previous studies have generated inconsistent results regarding whether RLS is associated with higher cardiovascular risk factors (CVRF) and mortality.

Design/Methods Case-control, longitudinal study of persons living in the community. RLS was diagnosed by a physician using the International RLS Study Group criteria. Age-standardized mortality ratios (SMR: observed/expected deaths) were calculated using age, gender-specific mortality tables (National Health Statistics, Burgos region).

Results Vital status was studied in a cohort of 235 patients, mean age of 61.6 + 15.8 years old, 181 women (78%) and 54 men (22%). Ninety six patients were diagnosed with RLS (41.4%), with a mean RLS duration of 14.1 + 1.9 years, and 136 (58.6%) were controls. This RLS cohort was followed for a median period of 11 years (2008 to 2019), and 5% were treated with dopaminergic drugs. As of September 2019, 6 RLS patients died (83.3% females), and the most frequent cause was cancer (66.7%). A total of 944 person-years of observations were available for survival analysis. The death rate in the RLS group, was similar to that expected for the general Spanish population (SMR=0.61, 95% CI: 0.27-1.36). There were no differences between the SMRs of men and women, however older patients with RLS (> 60 years old) had increased survival (SMR=0.41, 95% CI 0.18-0.93). After adjusting for age and gender, RLS was not associated with more frequent CVRF compared to non-RLS patients.

Conclusions To our knowledge, this is the first study assessing SMR in RLS. In this cohort, RLS did not affect survival.

Authors/Disclosures
Esther Cubo Delgado, MD, PhD, F�鶹��ýӳ�� (Fundacion Burgos Investigacion Salud CIF G09254616) PRESENTER	Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Cubo Delgado has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Cubo Delgado has received research support from Spanish health ministry. The institution of Dr. Cubo Delgado has received research support from European union grant.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��